FERRAU', Francesco
 Distribuzione geografica
Continente #
NA - Nord America 1.981
EU - Europa 1.663
AS - Asia 456
OC - Oceania 1
SA - Sud America 1
Totale 4.102
Nazione #
US - Stati Uniti d'America 1.979
IE - Irlanda 599
SE - Svezia 491
CN - Cina 428
IT - Italia 191
PL - Polonia 135
GB - Regno Unito 82
DE - Germania 41
FI - Finlandia 29
UA - Ucraina 28
FR - Francia 24
BE - Belgio 22
IN - India 14
VN - Vietnam 14
AT - Austria 8
RU - Federazione Russa 5
CZ - Repubblica Ceca 3
MX - Messico 2
AL - Albania 1
AU - Australia 1
CL - Cile 1
GR - Grecia 1
HR - Croazia 1
NL - Olanda 1
NO - Norvegia 1
Totale 4.102
Città #
Dublin 598
Chandler 514
Nyköping 308
Beijing 180
Ashburn 143
Warsaw 134
Jacksonville 123
Princeton 104
Medford 96
Dearborn 77
Ann Arbor 76
Des Moines 73
Messina 69
Cambridge 65
Lancaster 54
New York 42
Shenyang 39
Jinan 34
Boardman 28
Wilmington 26
Nanjing 22
Brussels 21
Tianjin 21
Seattle 18
Guangzhou 17
San Mateo 17
Dong Ket 14
Houston 14
Pune 14
Zhengzhou 14
Bremen 13
Hangzhou 12
Nanchang 12
Ningbo 12
Catania 10
Haikou 10
Taizhou 10
Woodbridge 10
Hebei 8
Vienna 8
Fairfield 7
Milan 7
Norwalk 7
Fort Worth 6
Fuzhou 6
Jiaxing 5
London 5
Turin 5
Changsha 4
Lanzhou 4
Rome 4
Vittoria 4
Clearwater 3
Genova 3
Helsinki 3
Los Angeles 3
Naples 3
Oxford 3
Ragusa 3
Augusta 2
Brooklyn 2
Carrara 2
Caserta 2
Cisano Bergamasco 2
Cividale del Friuli 2
Dachau 2
Empoli 2
Floridia 2
Hongtong 2
Padova 2
Piazza Armerina 2
Redwood City 2
Reggio Calabria 2
San Mauro Marchesato 2
Tuxtla Gutiérrez 2
Baotou 1
Brno 1
Castelfranco Veneto 1
Ceska 1
Cleveland 1
Corigliano Calabro 1
Dorking 1
Drogheda 1
Glasgow 1
Kemerovo 1
Las Vegas 1
Mainz 1
Mascalucia 1
Milazzo 1
Monserrato 1
Pedace 1
Phoenix 1
Qingdao 1
Redmond 1
Riva 1
Santa Clara 1
Somma Vesuviana 1
Strasbourg 1
Sydney 1
Syracuse 1
Totale 3.202
Nome #
Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide 101
Diabetes secondary to acromegaly: Physiopathology, clinical features and effects of treatment 97
Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas 89
Aggressive pituitary adenomas: the dark side of the moon 82
Cyberknife stereotactic treatment of pituitary adenomas: A single center experience using different irradiation schemes and modalities 79
GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly 75
Aggiornamento sulla chirurgia ipofisaria per via endoscopica: indicazioni, vantaggi e limiti 74
PRIMARY EMPTY SELLA IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK, REGARDLESS THE OCCURRENCE OF PITUITARY DYSFUNCTION 72
Course of Pregnancy in Cushing Disease under Different Management Approaches (No Treatment, Surgery, Gamma-Knife or Ketoconazole) 71
Multidisciplinary management of pituitary apoplexy 69
Peptide receptor radionuclide therapy with 111IN-DTPA-Octreotide in a woman with Cabergoline-resistant giant prolactinoma 68
P-57 Increased prevalence of acromegaly in an industrialized area of north-east of Sicily: a case-control study 68
Increased prevalence of acromegaly in a highly polluted area. 67
Resistance to somatostatin analogues is associated with GSTP1 gene methylation and AHR rs2066853 variant in acromegaly patients 64
Epidemiologia degli adenomi ipofisari nel nord-est della Sicilia 63
Thyroid nodules in growth hormone replaced patients. 63
Effectiveness and safety of long-term pegvisomant administration in patients with acromegaly not controlled by other therapies: experience of an Italian center. 61
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 61
Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing's disease: an Italian, multicenter study 60
Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas. 59
Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. 59
First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy 58
Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. 57
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 57
Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden 55
First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. 54
Pitfalls in the 2017 TNM Classification of Thyroid Carcinoma 53
High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures 53
Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma 52
An extremely rare association of TSH-secreting pituitary adenoma, metastatic neuroendocrine tumor and Cushing’s syndrome in a patient with MEN-1 gene mutation 52
Biochemical control and clinical improvement is induced by long-term pasireotide administration in the majority of patients with Cushing[apos]s disease persistent after pituitary surgery 52
Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly 51
Health-related quality of life in patients with Cushing's syndrome 51
Temozolomide-induced shrinkage of a pituitary carcinoma. 49
Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study 49
Effects of cyberknife radiotherapy treatment of pituitary adenomas 49
Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study 49
Comment to ‘glucocorticoid resistance syndrome caused by a novel nr3c1 point mutation’ by al argan et al. 48
Increased serum brain natriuretic peptide levels are a major predictor of myocardial hypertrophy in acromegalic patients. 47
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 47
Course of pregnancies in women with Cushing's disease treated by gamma-knife 45
The ubiquitin-specific peptidase 8 (USP8) gene is frequently mutated in adenomas causing Cushing's disease 45
Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis 44
An unusual case of idiopathic hyperprolactinemia 44
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 44
Absence of GNAS1 mutations in somatotropinomas from AIPmut positive patients: possible implications for phenotype. 43
Increased interleukin 22 circulating levels in patients with tumors involving the hypothalamic-pituitary region 43
Establishment of a protocol to extend the lifespan of human hormone-secreting pituitary adenoma cells 42
Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease. 41
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide 41
Pregnancy after azathioprine therapy for ulcerative colitis in a woman with autoimmune premature ovarian failure and Addison's disease: HLA haplotype characterization. 40
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 40
X-linked acrogigantism: a new condition of growth hormone excess. 39
Global epidemiology of acromegaly: A systematic review and meta-analysis 39
Landscape of familial isolated and young-onset pituitary adenomas: Prospective diagnosis in AIP mutation carriers 38
Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case 37
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches 37
Endocrinologia & Malattie del Metabolismo 36
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma 34
Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas 34
Sindromi ipercalcemiche 34
MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior. 34
A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score 34
Systemic comorbidities induce early vascular alterations in patients with active acromegaly. 33
Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly 33
What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study 33
Oral mucositis induced by treatment with soft gel formulation of levothyroxine 32
Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies 32
L'acromegalia 31
Clinical Consequences of Variable Results in the Measurement of Free Thyroid Hormones: Unusual Presentation of a Family with a Novel Variant in the THRB Gene Causing Resistance to Thyroid Hormone Syndrome 31
How to diagnose and manage Cushing's disease during pregnancy, when hypercortisolism is mild? 30
Metabolic comorbidities in Cushing's syndrome 30
The man with acromegaly who inspired the Shrek animated project. 30
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients 28
Tertiary hypercortisolism due to occult Cushing's syndrome 28
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis 27
null 27
Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence 27
Unique clinical picture in patients with X-linked acrogigantism 26
Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors 26
The Enhanced Proteasomal Degradation of AIP Mutant Proteins Is a Mechanism for AIP Deficiency in AIP mutation-Associated Pituitary Adenomas 25
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms 25
Metabolic syndrome in cushing's syndrome patients 25
Effects Of Epigenetic Changes In Gstp1 And Mgmt Gene On Clinicopathological Fatures Of Acromegaly Patients 25
Pituitary Adenomas Harboring AIP Mutations Exhibit Phenotype-Genotype Correlation, but No Association with the Germline FGFR4 G388R Variant or Somatic GNAS1 Mutations 25
GPR101 variants in acromegaly: results from a large series of patients. 24
Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report 24
Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications 23
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study 22
null 22
Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor 21
What we have to know about corticosteroids use during Sars-Cov-2 infection 21
Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas 20
Somatic mutations in USP8 are frequent events in pituitary tumors causing Nelson's syndrome 20
The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushing's disease 20
Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing’s disease: a monocentric experience in Southern Italy 18
Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma 17
What we have to know about corticosteroids use during Sars-Cov-2 infection 17
A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score 17
Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma 12
Totale 4.320
Categoria #
all - tutte 16.799
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.799


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201927 0 0 0 0 0 0 0 0 0 13 9 5
2019/2020415 16 3 3 7 6 86 33 29 19 142 60 11
2020/2021622 24 22 190 31 88 86 34 35 44 34 11 23
2021/2022673 1 69 12 32 18 10 29 23 10 97 120 252
2022/20231.795 171 187 81 142 117 162 37 95 717 15 43 28
2023/2024381 32 79 22 43 40 105 6 47 2 5 0 0
Totale 4.358